A fragmented approach to drug discovery created structural inefficiencies that drive up R&D costs.
Jeffrey Leiden, MD, PhD
Advertisement
Jeffrey Leiden, MD, PhD, is executive chairman at Vertex Pharmaceuticals.
Articles by Jeffrey Leiden, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Navigating Turbulent Markets: What Two Decades in Biotech Finance Taught Me About Building Companies That Last
2
Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion
3
FDA Approves Hepcludex as First and Only Approved Treatment for Chronic Hepatitis Delta Virus
4
The Implications of the Rising GLP-1 Market: Q&A with Kevin Dondarski
5